Tags Archive Navigation
icon
-
Media ReleaseNovartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020.
-
Media ReleaseDie Aktionäre von Novartis heissen an der Generalversammlung alle Anträge des Verwaltungsrats gut
-
Media ReleaseLes actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale annuelle
-
Media ReleaseNovartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
-
Media ReleaseNew Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children and durability 5+ years post-treatment
-
Media ReleaseNovartis signs initial agreement to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient for Roche’s Actemra/RoActemra®
-
Media ReleaseNovartis announces winners of the Innovation Prize for Assistive Tech, rewarding new technologies that could improve mobility and independence of people living with multiple sclerosis
-
Media ReleaseNovartis announces ambitious ESG targets to increase access to medicines and achieve full carbon neutrality
-
StoryNovartis Access impact evaluation: progress update on our work with Boston University
-
StoryMaking healthcare sustainable in the developing world
-
StoryLongevity with vitality: Japanese elders provide examples for healthy aging
-
StoryDigital health: providing opportunities for advocacy groups and a community for patients